Dengue serotype 2 attenuated strain
AssigneesSanofi Pasteur Limited, Centers for Disease Control and Prevention
InventorsRichard KINNEY, Claire Y.H. Kinney, Véronique Barban, Jean Lang, Bruno Guy
Life of this patent
Estimating the term…
Abstract
The invention relates to live attenuated VDV2 (VERO-Derived Vaccine Dengue serotype 2) strains which have been derived from the wild-type dengue-2 strain 16681 by passaging on PDK and Vero cells and nucleic acids thereof. The invention further relates to a vaccine composition which comprises a VDV2 strain.
Claims4
An isolated polyprotein encoded by SEQ ID No.1, or fragments thereof that comprise at least an arginine at position 9 of M protein, and/or a glutamic acid at position 228 of E protein, and/or a threonine at position 69 of NS3 protein, and/or a histidine at position 181 of NS3 protein, and/or a lysine at position 541 of NS5 protein, and/or a threonine at position 832 of NS5 protein.
Dependencies are inferred from the claim text.